Disparities With Systemic Therapies for Black Men Having Advanced Prostate Cancer: Where Do We Stand?

Autor:	Gong J; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA., Kim DM; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA., De Hoedt AM; Urology Section, Department of Surgery, Veterans Affairs Health Care System, Durham, NC., Bhowmick N; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA., Figlin R; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA., Kim HL; Division of Urology, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA., Sandler H; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA., Theodorescu D; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA.; Division of Urology, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA., Posadas E; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA., Freedland SJ; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA.; Urology Section, Department of Surgery, Veterans Affairs Health Care System, Durham, NC.; Division of Urology, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA.
Jazyk:	angličtina
Zdroj:	Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Jan 10; Vol. 42 (2), pp. 228-236. Date of Electronic Publication: 2023 Oct 27.
DOI:	10.1200/JCO.23.00949
Abstrakt:	Purpose: Prostate cancer represents the most common cancer diagnosis in Black men and is the second leading cause of cancer death in this population. Multilevel disparities have been well-documented in Black men with prostate cancer and play a role in poorer survival outcomes when compared with White men with prostate cancer. In this review, we highlight the changing trend in disparities for systemic therapy outcomes in Black men diagnosed with metastatic prostate cancer. Methods: We reviewed data from real-world registries and prospective clinical trials with a particular focus on equal access settings to compare outcomes to systemic therapies between Black and White men with metastatic prostate cancer. Results: In metastatic prostate cancer, there is growing evidence to suggest that Black men may have similar, if not better, outcomes to systemic therapies than White men with advanced disease, as corroborated by prospective studies and clinical trials where health care delivery and follow-up are more likely to be standardized. Conclusion: This review illustrates the importance of nonbiological drivers of racial disparities in Black men with advanced prostate cancer. Mitigating barriers to health care access and delivery as well as including participation in clinical trials will be pivotal to ongoing efforts to address disparities in systemic therapy outcomes for Black men with metastatic prostate cancer.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu